Molecular Partners AG
OTC: MLLCF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Patrick Amstutz
- Employees
- 142
- Headquarters
- Schlieren, Switzerland
- IPO year
- 2018
- Market cap
- $135.0M
- Website
- https://www.molecularpartners.com
Loading MLLCF…
Loading profile data…Frequently asked questions about MLLCF
What does Molecular Partners AG (MLLCF) do?
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging...
Where does MLLCF trade?
Molecular Partners AG (MLLCF) trades on the Other OTC.
What sector is MLLCF in?
Molecular Partners AG (MLLCF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Molecular Partners AG?
Patrick Amstutz is the chief executive officer of Molecular Partners AG (MLLCF).
Where is Molecular Partners AG headquartered?
Molecular Partners AG is headquartered in Switzerland.
Does MLLCF pay a dividend?
Molecular Partners AG (MLLCF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MLLCF go public?
Molecular Partners AG (MLLCF) completed its initial public offering in 2018.